Plain-English translation of NCT07383246 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new type of imaging scan called 68Ga-CTR-FAPI PET-CT can help surgeons see and remove medullary thyroid cancer more effectively. Medullary thyroid cancer is a rare and serious type of thyroid cancer, and surgery is currently the best treatment. The imaging scan works by detecting special proteins that cancer cells produce, which may help surgeons identify exactly where the cancer is located and avoid removing healthy tissue.
Standard imaging tests often cannot show the full extent of medullary thyroid cancer, making it difficult for surgeons to know exactly how much tissue to remove during surgery. This new imaging technology may provide a clearer picture of where the cancer is, helping surgeons remove all cancerous areas while preserving as much healthy tissue as possible.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will have the new imaging scan (68Ga-CTR-FAPI PET-CT) to help plan your surgery; the other group will have surgery planned using standard methods. Either way, you will have surgery to remove the cancer. After surgery, you will have follow-up visits to check how well the treatment worked, including blood tests to measure cancer markers about one month after your operation. You should expect visits at baseline, before surgery, and then for follow-up checks after your operation.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China